These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 4352111)

  • 1. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
    [No Abstract]   [Full Text] [Related]  

  • 2. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
    [No Abstract]   [Full Text] [Related]  

  • 3. Malaria antibody levels in patients with nasopharyngeal carcinoma.
    Yadav M; Prasad U
    Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report.
    Malik MO; Banatvala J; Hutt MS; Abu-Sin AY; Hidaytallah A; El-Hadi AE
    J Natl Cancer Inst; 1979 Feb; 62(2):221-4. PubMed ID: 216831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on antibody surveillance to EB virus-induced antigen in patients with sarcoidosis and nasopharyngeal carcinoma by indirect immunofluorescence.
    Naito M; Akiyama Y; Kato S; Tachibana T; Sakai T
    Biken J; 1973 Dec; 16(4):141-8. PubMed ID: 4363326
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.
    Chatani M; Teshima T; Inoue T; Yoshino K; Ikegami N; Hirai K; Shimakage M
    Laryngoscope; 1991 Jun; 101(6 Pt 1):626-9. PubMed ID: 1645832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution of EBV-VCA and EA antibody in the general population in a high incidence area of nasopharyngeal carcinoma].
    Liu YX
    Zhonghua Zhong Liu Za Zhi; 1983 Sep; 5(5):337-9. PubMed ID: 6317314
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between natural cytotoxicity activity, Epstein-Barr virus (EBV) antibody titer and clinical status in nasopharyngeal carcinoma patients].
    Mu M
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1988; 23(1):46-9. PubMed ID: 2856431
    [No Abstract]   [Full Text] [Related]  

  • 10. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
    Kottaridis SD; Goula I; Kiparissiadis P
    Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
    [No Abstract]   [Full Text] [Related]  

  • 11. Nasopharyngeal carcinoma and Epstein-Barr virus. III. The detection of anti-nuclear antibodies.
    Lynn TC; Hsu MM; Hsieh T; Tu SM; Hamajima K
    Jpn J Exp Med; 1976 Oct; 46(5):289-95. PubMed ID: 189106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The diagnosis of nasopharyngeal carcinoma (author's transl)].
    Arnold W; Nakazima A; Wang YB; Vosteen KH; Brunner H; Göbel U
    HNO; 1980 Aug; 28(8):247-60. PubMed ID: 6254933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.
    Henle W; Henle G; Ho HC; Burtin P; Cachin Y; Clifford P; de Schryver A; de-Thé G; Diehl V; Klein G
    J Natl Cancer Inst; 1970 Jan; 44(1):225-31. PubMed ID: 11515035
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
    Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
    Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
    [No Abstract]   [Full Text] [Related]  

  • 15. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroepidemiological studies on carcinoma of the nasopharynx.
    Lin TM; Yang CS; Chiou JF; Tu SM; Lin CC; Liu CH; Chen KP; Ito Y; Kawamura A; Hirayama T
    Cancer Res; 1973 Nov; 33(11):2603-8. PubMed ID: 4355974
    [No Abstract]   [Full Text] [Related]  

  • 18. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
    Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
    Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occult nasopharyngeal carcinoma (author's transl)].
    Schmauz R; Hoppe W; zur Hausen H
    Dtsch Med Wochenschr; 1975 Dec; 100(49):2527-9. PubMed ID: 172307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.